This is not the most recent version of this material.
For an updated version, please see the relevant topic page.
CAR-T Therapies: Evidence Report
ICER’s report on the comparative clinical effectiveness and value of tisagenlecleucel (KymriahTM, Novartis) and axicabtagene ciloleucel (YescartaTM, Kite Pharma/Gilead). This report will be subject to public deliberation during a meeting of CTAF on March 2, 2018.View All Materials on this Topic or Go Back to View More Materials